GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Principia Biopharma Inc (NAS:PRNB) » Definitions » Interest Coverage

Principia Biopharma (Principia Biopharma) Interest Coverage : N/A (As of Jun. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Principia Biopharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Principia Biopharma's Operating Income for the three months ended in Jun. 2020 was $9.88 Mil. Principia Biopharma's Interest Expense for the three months ended in Jun. 2020 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Principia Biopharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Principia Biopharma's Interest Coverage or its related term are showing as below:


PRNB's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 125.655
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Principia Biopharma Interest Coverage Historical Data

The historical data trend for Principia Biopharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Principia Biopharma Interest Coverage Chart

Principia Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Interest Coverage
- - No Debt No Debt

Principia Biopharma Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt N/A N/A

Competitive Comparison of Principia Biopharma's Interest Coverage

For the Biotechnology subindustry, Principia Biopharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Principia Biopharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Principia Biopharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Principia Biopharma's Interest Coverage falls into.



Principia Biopharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Principia Biopharma's Interest Coverage for the fiscal year that ended in Dec. 2019 is calculated as

Here, for the fiscal year that ended in Dec. 2019, Principia Biopharma's Interest Expense was $0.00 Mil. Its Operating Income was $-58.77 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Principia Biopharma had no debt (1).

Principia Biopharma's Interest Coverage for the quarter that ended in Jun. 2020 is calculated as

Here, for the three months ended in Jun. 2020, Principia Biopharma's Interest Expense was $0.00 Mil. Its Operating Income was $9.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $12.80 Mil.

GuruFocus does not calculate Principia Biopharma's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Principia Biopharma  (NAS:PRNB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Principia Biopharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of Principia Biopharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Principia Biopharma (Principia Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
220 East Grand Avenue, South San Francisco, CA, USA, 94080
Principia Biopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapies for immunology and oncology. Its proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities. The company pipeline products include PRN1008 and PRN2246 and PRN1371 under BTK franchise.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Stefani Wolff officer: Chief Development Officer C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Martin Babler director, officer: President, CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
Shao-lee Lin director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
David M Goldstein officer: Chief Scientific Officer C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Roy C. Hardiman officer: Chief Business Officer C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Christopher Y Chai officer: Chief Financial Officer 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Principia Biopharma (Principia Biopharma) Headlines

From GuruFocus